Vinod Lala
Jersey City, NJNPI 1144259383
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,170 of the $20,243 with a category attached, or 79.9%. Merck accounts for 86.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $18,144 and has fallen 98.1% since, to $337 in 2025.
Across 196 payments — averaging $103.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18K
- AstraZeneca$773
- Lilly USA, LLC$436
- Novo Nordisk$365
- Boehringer Ingelheim$219
- Boston Scientific$145
- plus $802 from 15 others
What the payments were for
- Speaking & faculty fees$16,17080%
- Travel & lodging$9305%
- Food & beverage$3,06015%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 44 | $17,502 |
| AstraZeneca(2 entities) | 35 | $773 |
| Lilly USA, LLC | 36 | $436 |
| Novo Nordisk | 24 | $365 |
| Boehringer Ingelheim | 15 | $219 |
| Boston Scientific | 1 | $145 |
| Seapearl East, Inc | 1 | $126 |
| AbbVie(2 entities) | 8 | $117 |
| Amgen | 8 | $111 |
| Shire North American Group Inc | 5 | $72 |
| Sanofi | 1 | $67 |
| Amarin Pharma, Inc. | 1 | $59 |
| Johnson & Johnson | 4 | $57 |
| Abbott | 3 | $44 |
| Vistapharm, Inc. | 3 | $41 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Corcept Therapeutics | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Insulet Corporation | 1 | $15 |
| Pfizer | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$16,825
- TEZSPIRE$243
- WATCHMAN FLX$145
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Losartan Potassium | 12 | $53 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.